Development of Plasmonic Cu2O/Cu Composite Arrays as Visible- and Near-Infrared-Light-Driven Plasmonic Photocatalysts.

We describe efficient visible- and near-infrared (vis/NIR) light-driven photocatalytic properties of hybrids of Cu2O and plasmonic Cu arrays. The Cu2O/Cu arrays were prepared simply by allowing a Cu half-shell array to stand in an oxygen atmosphere for 3 h, which was prepared by depositing Cu on two-dimensional colloidal crystals with a diameter of 543 or 224 nm. The localized surface plasmon resonances (LSPRs) of the arrays were strongly excited at 866 and 626 nm, respectively, at which the imaginary part of the dielectric function of Cu is small. The rate of photodegradation of methyl orange was 27 and 84 times faster, respectively, than that with a Cu2O/nonplasmonic Cu plate. The photocatalytic activity was demonstrated to be dominated by Cu LSPR excitation. These results showed that the inexpensive Cu2O/Cu arrays can be excellent vis/NIR-light-driven photocatalysts based on the efficient excitation of Cu LSPR.

Efficient Photocurrent Enhancement from Porphyrin Molecules on Plasmonic Copper Arrays: Beneficial Utilization of Copper Nanoanntenae on Plasmonic Photoelectric Conversion Systems.

We demonstrated the usefulness of Cu light-harvesting plasmonic nanoantennae for the development of inexpensive and efficient artificial organic photoelectric conversion systems. The systems consisted of the stacked structures of layers of porphyrin as a dye molecule, oxidation-suppressing layers, and plasmonic Cu arrayed electrodes. To accurately evaluate the effect of Cu nanoantenna on the porphyrin photocurrent, the production of Cu2O by the spontaneous oxidation of the electrode surfaces, which can act as a photoexcited species under visible light irradiation, was effectively suppressed by inserting the ultrathin linking layers consisting of 16-mercaptohexadecanoic acid, titanium oxide, and poly(vinyl alcohol) between the electrode surface and porphyrin molecules. The reflection spectra in an aqueous environment of the arrayed electrodes, which were prepared by thermally depositing Cu on two-dimensional colloidal crystals of silica with diameters of 160, 260, and 330 nm, showed clear reflection dips at 596, 703, and 762 nm, respectively, which are attributed to the excitation of localized surface plasmon resonance (LSPR). While the first dip lies within the wavelengths where the imaginary part of the Cu dielectric function is moderately large, the latter two dips lie within a region of a quite small imaginary part. Consequently, the LSPR excited at the red region provided a particularly large enhancement of porphyrin photocurrent at the Q-band (ca. 59-fold), compared to that on a Cu planar electrode. These results strongly suggest that the plasmonic Cu nanoantennae contribute to the substantial improvement of photoelectric conversion efficiency at the wavelengths, where the imaginary part of the dielectric function is small.

Extraordinary enhancement of porphyrin photocurrent utilizing plasmonic silver arrays.

We demonstrate up to ∼630-fold enhancement of the photocurrent from a porphyrin monolayer on a plasmonic Ag-array electrode showing plasmon absorption in the Q-band region relative to that on a planar Ag electrode. The photocurrent obtained by the Q-band excitation in the plasmonic electrodes even exceeded that obtained by the Soret-band excitation in a normal, nonplasmonic electrode.

Long-term efficacy and safety of the small-sized ß2-microglobulin adsorption column for dialysis-related amyloidosis.

Dialysis-related amyloidosis (DRA) is one of the major complications often seen in long-term dialysis patients, and is one of the factors that decreases quality of life. ß2-microglobulin (ß2-m) is considered to be a major pathogenic factor in dialysis-related amyloidosis. The Lixelle adsorbent column, with various capacities, has been developed to adsorb ß2-m from the circulating blood of patients with dialysis-related amyloidosis. Using a minimum type of ß2-m-adsorbing column (Lixelle S-15), we evaluated its therapeutic efficacy and safety in dialysis patients. Seventeen hemodialysis patients with DRA were treated with the S-15 column for one year. Treatment was performed three times a week in this study. During the study period, pinch strength, visual analog scale for joint pain, and activities of daily living were evaluated every three months, and blood sampling was performed every six months. After one year's treatment with the S-15 column, the ß2-m level decreased from 29.3±9.6mg/L to 24.7±5.1mg/L (P<0.05), and the high sensitive C-reactive protein level decreased from 2996±4380ng/mL to 1292±1774ng/mL. After one year of S-15 column use, pinch strength increased from 5.9±3.0pounds to 7.2±3.2pounds (P<0.05), and the visual analog scale for joint pain and activities of daily living score also improved. Long-term use of the Lixelle S-15 column is safe and effective for improvement of quality of life in chronic dialysis patients. Improvement of chronic inflammation may be one of the mechanisms through which the beneficial effects of the column is effected.

Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.

Sevelamer improves hyperphosphatemia without increasing the calcium load. However, it remains unknown whether sevelamer restores bone metabolism in hemodialysis patients with low bone turnover osteodystrophy and hypoparathyroidism. We investigated the changes in serum intact parathyroid hormone (iPTH) and bone metabolic marker levels after replacing calcium carbonate with sevelamer in these patients. We also conducted stratified analysis based on patient background and multivariate analysis to determine the factors affecting these parameters. During sevelamer replacement therapy, serum calcium and phosphate concentrations, and the calcium phosphate product were measured at 0, 1, 3, and 6 months. Serum iPTH, bone alkaline phosphatase and osteocalcin concentrations were measured at 0 and 6 months. In hemodialysis patients (71 men and 46 women, 63 +/- 12 years old) serum calcium levels and the calcium phosphate product decreased significantly at 1 month. Serum iPTH, bone alkaline phosphatase and osteocalcin levels increased significantly at 6 months. Increases in serum iPTH concentrations were observed in all stratified groups. Significant increases in serum bone alkaline phosphatase and osteocalcin concentrations were found only in the relative hypoparathyroidism group (iPTH levels > or =51.5 pg/mL, the median pretreatment level). Multivariate analysis showed that the factors affecting change in serum iPTH level are baseline serum iPTH, baseline calcium level (> or =9.5 mg/dL), and dialysis duration of 10 years or longer. Sevelamer appears useful for the treatment of hyperphosphatemia in these patients. Particularly, in the relative hypoparathyroidism group, the iPTH secretory response is probably enhanced and bone turnover may have been improved as a result of reducing the calcium load.